Akeso, Inc. is a Chinese biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative antibody drugs. Established in 2012, it listed on the Hong Kong Stock Exchange in 2020 under stock code 9926. The company reports a broad pipeline across oncology, autoimmune, inflammation, and metabolic diseases.
China's regulatory reforms since 2015 have streamlined clinical trial and drug approval processes, accelerating development of advanced therapies like CAR-T and bispecific antibodies. These changes have boosted investor confidence and created opportunities for global pharmaceutical partnerships with Chinese biotech companies that have innovative pipelines but lack international marketing capabilities.
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
Summit Therapeutics will participate in three investor conferences in March 2026, following FDA acceptance of its BLA for ivonescimab in lung cancer with a PDUFA date of November 14, 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07755371 |
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps |
NOT_YET_RECRUITING | PHASE2 |
| NCT07700979 |
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07669779 |
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer |
RECRUITING | PHASE2 |
| NCT07636772 |
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07635290 |
Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07623356 |
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07619001 |
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations |
NOT_YET_RECRUITING | PHASE1 |
| NCT07591090 |
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer |
RECRUITING | PHASE2 |
| NCT07566247 |
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor |
NOT_YET_RECRUITING | PHASE1 |
| NCT07560124 |
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
